Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Have Distinct Prediagnostic Blood Biochemical Profiles
Open Access
- 30 October 2025
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 99 (4) , 844-856
Abstract
Objective: Identifying modifiable factors influencing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) risk is important for prevention. Blood biomarkers, particularly cholesterol, have been associated with neurodegenerative risk, but findings in ALS are inconsistent, and data on FTD are limited. Methods: We conducted a population‐based cohort study using UK primary care records from QResearch linked with Hospital Episode Statistics. Adults with biomarker data recorded between 1998 and 2023 were included. We examined associations of low‐ and high‐density lipoprotein cholesterol (LDL‐C and HDL‐C), total cholesterol, triglycerides, creatinine, creatine kinase, and HbA1c with ALS and FTD risk. Cox proportional hazards models were used to estimate associations. Two‐sample Mendelian randomization (MR) was applied to explore genetically predicted associations of selected biomarkers. Results: There were up to 2,695 ALS and 781 FTD diagnoses, with a median follow‐up duration of 9.4 and 10.5 years, respectively. Higher LDL‐C (hazard ratio [HR] per 1‐SD = 1.07, 95% confidence interval [CI] = 1.02–1.11) and total cholesterol levels (HR per 1‐SD = 1.06, 95% CI = 1.02–1.10) were linearly associated with higher ALS risk. Age‐stratified analysis showed a stronger association for total cholesterol in those ≥ 60 years (HR per 1‐SD = 1.08, 95% CI = 1.04–1.13, P interaction = 0.003). Higher creatinine was inversely associated with FTD risk (HR per 1‐SD = 0.90, 95% CI = 0.83–0.97), supported by MR (odds ratio [OR] inverse variance weighted ( IVW ) , per 1‐SD = 0.73, 95% CI = 0.56–0.96). HbA1c showed a U‐shaped association with FTD (P non‐linearity = 0.006). Interpretation: LDL and total cholesterol may provide insights into early disease changes or the etiology of ALS, whereas creatinine and HbA1c may be relevant for FTD. Research in monogenic ALS and FTD is needed to determine whether these biomarkers inform targeted prevention or intervention strategies. ANN NEUROL 2026;99:844–856Keywords
This publication has 59 references indexed in Scilit:
- HbA1c variability associated with dementia risk in people with type 2 diabetesAlzheimer's & Dementia, 2024
- Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 DiabetesJAMA Neurology, 2023
- Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2021
- Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversionAnnals of Neurology, 2018
- Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20‐year follow‐up of the Swedish AMORIS cohortAnnals of Neurology, 2017
- Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and CreatinineJAMA Neurology, 2014
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosisJournal of Neurology, 2010
- Mendelian randomization: Using genes as instruments for making causal inferences in epidemiologyStatistics in Medicine, 2008
- Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress–induced death of motor neurons in amyotrophic lateral sclerosisAnnals of Neurology, 2002